INSILICO MEDICINE InSilico Medicine Cayman TopCo

英矽智能

03696.HK

Operates an AI-driven drug discovery and development company using its proprietary generative AI platform Pharma.AI to discover drug candidates, deriving revenue primarily from out-licensing and collaboration arrangements with international pharmaceutical companies globally.

Filings

The documents are on HKEXnews; we link to the originals.

Matters the filing discloses

From the company’s latest filing; open a kind of matter to see how other companies disclosed it.

• Customer concentration
• Supplier concentration
• Reliance on platforms, partners or licences
• Single product, business line or region
• Outsourced production (OEM / contract manufacturing)
• Losses and path to profitability
• Net current liabilities or net liabilities
• Cash burn and runway
• Preferred shares and fair-value liabilities
• Adverse change after the track record
• Non-IFRS measures and adjustments
• Non-recurring gains and losses
• Related-party transactions and balances
• Material share-based payments
• Chapter 18A biotech